LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Accueil・Liste d'Actions・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Fermé

SecteurSoins de santé

19.39 -3.72

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

19.3

Max

20.36

Chiffres clés
By Trading Economics
Revenu	25M -43M
Ventes	-3.6M 65M
BPA	-0.48
Marge bénéficiaire	-65.788
Employés	298
EBITDA	-16M -31M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+97.28% upside

Dividendes
By Dow Jones
Prochains Résultats	3 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	42M 1.9B
Ouverture précédente	23.11
Clôture précédente	19.39

Sentiment de l'Actualité

By Acuity

100%

320 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

9.91 / 14.15 Support & Résistance

Syndax Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 mai 2026, 23:53 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mai 2026, 22:47 UTC

Actions en Tendance

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mai 2026, 22:16 UTC

Acquisitions, Fusions, Rachats

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mai 2026, 22:00 UTC

Principaux Mouvements du Marché

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mai 2026, 18:09 UTC

Principaux Mouvements du Marché

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mai 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mai 2026, 23:07 UTC

Acquisitions, Fusions, Rachats

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mai 2026, 23:06 UTC

Acquisitions, Fusions, Rachats

UOB: Share Sale Agreements Entered With Singland Properties

17 mai 2026, 23:05 UTC

Acquisitions, Fusions, Rachats

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Acquire Stake for $389 Million

17 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mai 2026, 16:27 UTC

Acquisitions, Fusions, Rachats

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mai 2026, 15:26 UTC

Acquisitions, Fusions, Rachats

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:59 UTC

Acquisitions, Fusions, Rachats

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mai 2026, 21:50 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 20:19 UTC

Actions en Tendance

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mai 2026, 19:41 UTC

Acquisitions, Fusions, Rachats

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mai 2026, 18:35 UTC

Résultats

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparaison

Variation de prix

Syndax Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

97.28% hausse

Prévisions sur 12 Mois

Moyen 39.91 USD 97.28%

Haut 57 USD

Bas 29 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

9.91 / 14.15Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

320 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.